Navigation Links
Omeros Submits New Drug Application to U.S. FDA for OMS302
Date:8/1/2013

m. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. These statements include, but are not limited to, Omeros' expectations regarding the potential benefits of OMS302; the timing for submission of a Marketing Authorization Application for OMS302 to the European Medicines Agency; potential OMS302 marketing approval; the date of the expected market launch of OMS302, if regulatory approval is obtained; the potential benefits of Omeros' products; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Qua
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned ... market share and grab a foothold in the hydroponic, hemp ... capabilities and a presence in the sector, and recently partnering ... growth of hemp and medical marijuana, iMD is committing to ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... Inc. (NYSE: MTD ) today announced the webcast ... in New York on Wednesday, September 21, 2011, at 9:00 ... presentation, visit the investor relations page on the Company,s Web ... will be available for seven days. METTLER TOLEDO ...
... JERUSALEM, Sept. 14, 2011 Chiasma, Inc., a privately held ... will present an overview of the Company at the UBS ... New York, on Monday, September 19, 2011 at 1:30 PM. ... form of octreotide acetate being developed first for the oral ...
Cached Medicine Technology:Chiasma to Present at the UBS Global Life Sciences Conference 2
(Date:1/22/2015)... January 22, 2015 The Incredible Bulk is ... Pakulski to increase lean muscle by up to 30lbs in ... the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. ... is a step-by-step, scientific diet formula that allows the body ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... News) -- Poor growth, heart problems and delays in ... mild to moderately impaired kidney function, new research says. ... disease also found that even when some of them ... blood pressure and metabolic issues, the conditions became more ...
... News) -- The U.S. Food and Drug Administration on ... for the treatment of an often lethal form of melanoma. ... in about half of melanomas, the deadliest form of skin ... fight against metastatic melanoma and the advancement of treatment for ...
... reduce health care costs arising from pressure ulcers, commonly ... elderly patients in emergency departments, according to new research ... elderly patients are at high risk for pressure ulcers ... surfaces. The researchers found that while the average cost ...
... , WEDNESDAY, Aug. 17 (HealthDay News) -- Researchers have ... in identifying women who have a higher risk of ... This particular antibody, which was detected in blood, develops ... mesothelin. This protein is present in advanced ovarian cancer. ...
... spent annually on treating chronic wounds on patients in the ... life of more than six million people who have them. ... ulcers are related to venous disease (conditions related to or ... options are available, but the quality of evidence showing which ...
... HealthDay Reporter , TUESDAY, Aug. 16 (HealthDay ... with bipolar disorder are better controlled by antipsychotic ... suggests. Researchers from Italy and the United ... haloperidol (Haldol) along with later formulations of risperidone ...
Cached Medicine News:Health News:FDA Approves Novel Melanoma Drug 2Health News:FDA Approves Novel Melanoma Drug 3Health News:Better mattresses improve care, cut hospital costs: U of T study 2Health News:Blood Antibody May Signal Start of Ovarian Cancer 2Health News:Blood Antibody May Signal Start of Ovarian Cancer 3Health News:Johns Hopkins Evidence-based Practice Center awarded $475,000 project 2Health News:Johns Hopkins Evidence-based Practice Center awarded $475,000 project 3Health News:Antipsychotics Best for Controlling Mania: Study 2Health News:Antipsychotics Best for Controlling Mania: Study 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: